LIQUIDIA CORP (LQDA) competitors & alternatives
Health Care · NASDAQ
LIQUIDIA CORP (LQDA)'s top competitors and alternatives — its most similar public companies — include Gilead Sciences (GILD), United Therapeutics (UTHR), Insmed (INSM), MANNKIND CORP (MNKD), TREVI THERAPEUTICS INC (TRVI), TENAX THERAPEUTICS INC (TENX), TECTONIC THERAPEUTIC INC (TECX), SAVARA INC (SVRA), INHIBIKASE THERAPEUTICS INC (IKT), Roivant Sciences (ROIV), Tenaya Therapeutics, Inc. (TNYA) and PRECIGEN INC (PGEN). These are LIQUIDIA CORP's closest public-company peers by sub-industry, sector and business themes and is informational only — not financial advice.
Top LQDA competitors & alternatives
-
Gilead SciencesGILDHealth Care
A diversified biopharmaceutical company pioneering viral disease treatments, cell therapies, and oncology medicines with a portfolio spanning HIV, hepatitis,…
$130.34 (as of 2026-07-22) · market cap $163.6B
-
United TherapeuticsUTHRHealth Care
United Therapeutics is a rare disease specialist dominating pulmonary hypertension treatment through multiple treprostinil delivery formats while pursuing…
$527.07 (as of 2026-07-22) · market cap $22.7B
-
InsmedINSMHealth Care
A biopharmaceutical company with approved rare respiratory therapies (ARIKAYCE for MAC lung disease, BRINSUPRI for bronchiectasis) and a pipeline in…
$106.64 (as of 2026-07-22) · market cap $23.4B
-
MANNKIND CORPMNKDHealth Care
MannKind is a biopharmaceutical company specializing in drug-device combinations, including inhaled therapies and on-body infusors, to treat cardiometabolic…
$3.84 (as of 2026-07-22) · market cap $1.2B
-
TREVI THERAPEUTICS INCTRVIHealth Care
Trevi Therapeutics is a clinical-stage biotech developing Haduvio, an oral, non-scheduled dual-action opioid receptor drug, to treat chronic cough associated…
$17.36 (as of 2026-07-22) · market cap $2.5B
-
TENAX THERAPEUTICS INCTENXHealth Care
A Phase 3 development-stage pharmaceutical company developing novel cardiopulmonary therapies, primarily levosimendan for pulmonary hypertension and imatinib…
$14.79 (as of 2026-07-22) · market cap $418M
-
TECTONIC THERAPEUTIC INCTECXHealth Care
A biotechnology company using its proprietary GEODe™ platform to unlock therapeutic protein and antibody treatments for difficult-to-target GPCR-related…
$31.59 (as of 2026-07-22) · market cap $594M
-
SAVARA INCSVRAHealth Care
Savara is a clinical-stage biopharmaceutical company dedicated to developing innovative inhalable therapies for rare respiratory diseases.
$5.65 (as of 2026-07-22) · market cap $1.2B
-
INHIBIKASE THERAPEUTICS INCIKTHealth Care
A pre-revenue biotech company developing IKT-001, a novel therapeutic targeting pulmonary arterial hypertension, currently in Phase 3 clinical trials with no…
$2.17 (as of 2026-07-22) · market cap $287M
-
Roivant SciencesROIVHealth Care
Roivant Sciences is a biopharma-tech incubator that uses a 'Vant' subsidiary model and computational discovery tools to accelerate the development of…
$34.91 (as of 2026-07-22) · market cap $25.1B
-
Tenaya Therapeutics, Inc.TNYAHealth Care
Tenaya Therapeutics is a clinical-stage biopharmaceutical company leveraging gene therapy and small molecule platforms to develop curative, precision-medicine…
$0.79 (as of 2026-07-22) · market cap $171M
-
PRECIGEN INCPGENHealth Care
Gene therapy precision medicine company with FDA-approved adenoviral immunotherapy for HPV-driven respiratory disease and a development pipeline of CAR-T and…
$5.32 (as of 2026-07-22) · market cap $1.9B
Not quite? Describe exactly what you want →
Peers are LIQUIDIA CORP's closest public companies by shared sub-industry, sector and business themes. See the full profile: LIQUIDIA CORP (LQDA).
Last updated 2026-07-22.
Informational only — NOT financial advice. Company data is sourced from SEC EDGAR + Finnhub and shown with its as-of date.